UCSF home page UCSF home page About UCSF Search UCSF UCSF Medical Center
UCSF navigation bar
banner
IP Management Overview
Frequently Asked Questions
Working With OTM
The Staff at OTM
Forms
Disclosure Forms
Material Transfers (MTA)
Available Technologies
UC Policies
Laboratory Notebooks
Related Sites
UCSF Sites of Interest
Research News

OFFICE OF TECHNOLOGY MANAGEMENT

AVAILABLE TECHNOLOGIES

METHOD FOR REDUCING SURFACTANT INACTIVATION IN PULMONARY SURFACTANT THERAPY

Background:

Human lung surfactant is a complex mixture of lipids and proteins that reduces surface tension in the lung, enabling normal breathing. Lack of effective surfactant results in Respiratory Distress Syndrome (RDS), a potentially fatal condition seen in premature infants and in adults with lung infection or trauma. While replacement lung surfactant (RLS) therapy has revolutionized neonatal RDS treatment, it is relatively ineffective in adults. Even with neonatal RDS, up to 30% of infants do not respond to RLS therapy. This failure in RLS therapy has been attributed, at least in part, to inactivation of the replacement lung surfactant in distressed lungs.

Description:

Researchers at the University of California, San Francisco, have discovered that inactivation of surfactants by endogenous substances present in the lung can be significantly reduced by administration of either ionic or nonionic polymers. Ionic polymers are particularly effective, and have the advantage that lung epithelial cells produce them endogenously. The polymers may therefore be useful in the design of second-generation surfactants for use in RLS.

Advantages:

Addition of the polymers to surfactants may dramatically increase the effectiveness of replacement lung surfactant therapy.

Applications:

Surfactant with polymer may be useful in the treatment of:

  • Respiratory Distress Syndrome of infants and adults.
  • Meconium aspiration pneumonia in newborns.
  • Acute lung injury.
  • Conditions with thick airway secretions such as cystic fibrosis, severe asthma, bronchiectasis, and pneumonia.

Issued Patents: US Patent No. 6,180,142

Case No.: SF98-108

 

If you would like to receive further information about this technology and potential licensing opportunities, please contact:

Sunita Rajdev, Ph.D.
Licensing Officer
(415) 353-4470 phone
(415) 348-1579 fax
Sunita Rajdev

Reference: OTM Case #SF98-108

OTM Home Page | Search | Feedback | Site Map | Help | Top of Page
IP Management Overview | Frequently Asked Questions | Working With the OTM | The Staff at OTM
Forms | Disclosure Forms | Material Transfers (MTA) | Available Technologies
UC Policies | Laboratory Notebooks | Related Sites | UCSF Sites of Interest | Research News